Rapport Therapeutics, which emerged out of Johnson & Johnson's neuroscience unit last year, has submitted its pitch for a ...
The European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with Pfizer and BioNTech over ...
The FDA has work to do to earn the confidence of certain groups of people who do not trust the agency, a study published ...
The European Medicines Agency is taking aim at preterm birth drugs, with the agency’s safety committee recommending that ...
Korean biotech HLB and its China-based partner Jiangsu Hengrui Pharmaceuticals said Friday that the FDA rejected their drug ...
Telix Pharmaceuticals, a radiopharma drug and diagnostics maker, has started its march toward a listing on the Nasdaq, ...
Erasca is looking for a refresh as it drops several early-stage cancer assets, picks up new ones from China and raises cash ...
Bayer shared more data on its menopause symptom drug elinzanetant, which demonstrates how the treatment triumphed over ...
Jim Burns was looking for his next post after his latest venture in biotech, a gene therapy startup known as Locanabio, shut ...
A new obesity biotech has entered the field — and it has $400 million from well-known life sciences investors to test ...
British drugmaker GSK will sell off the rest of its share in Haleon after slowly selling off multibillion-dollar pieces of ...
Roche is back to square one for finding a partner to carry forward its culled Angelman syndrome drug. Last June, the Swiss ...